To investigate whether statin therapy utilizing the drug Lipitor (atorvastatin) might be
effective in preventing short-and long-term atrial fibrillation following a left atrial
ablation procedure. We further hypothesize this reduction will result from diminished
peri-procedural inflammation, which will be reflected in lower CRP values.
Although pharmacologic therapy is the traditional mainstay of therapy for AF, curative
therapy has recently become possible.
There is growing evidence that inflammation may be involved in the pathogenesis of AF.
C-reactive protein (CRP), a sensitive marker of systemic inflammation, is increased in
patients with AF compared with patients in sinus rhythm. Elevated CRP levels are associated
with increased likelihood of new onset AF and with recurrence of AF after successful
cardioversion. Clinical and basic laboratory evidence suggests that, in addition to being
potent lipid-lowering agents, statins may also have anti-inflammatory properties and
protective effect against AF.
125 eligible patients with AF, undergoing left atrial ablation, will be randomly assigned in
a 1:1 ratio to receive daily 80 mg of atorvastatin or placebo in a double-blind fashion for
3 months after their ablation procedure.
Patients will have baseline lipids, CRP, endothelial function tests (PAT)and Quality of Life
(QoL) surveys compared with testing at 3 months post ablation.
- Patients > or = to 18 years of age
- Clinically indicated left atrial ablation procedure for atrial fibrillation
- Exclusion criteria are known malignancy
- Known inflammatory disease
- Surgery or trauma or myocardial infarction in the previous month
- Known contraindication to statin therapy
- Elevated liver enzymes two times normal
- Patients already receiving therapy with any statin, niacin or fibrates at the time of